Skip to content
Screener

PTC Therapeutics PTCT Q1 2026 earnings

Reported May 7, 2026 · After market close

Revenue$272.6MBeat by $55.1M
EPS-$0.03Beat by $0.42
Revenue estimate$217.4M
EPS estimate-$0.45

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$303.9M
EPS estimate$0.29

Financials

Q1 2026

Income statement

See full
Revenue$272.6M-76.8%
Operating income$45.0M-95.4%
Net income-$2.8M-100%
EPS (diluted)-$0.03-100%

Balance sheet

See full
Cash & equivalents$834.0M-43.7%
Total debt$395.1M+0.1%
Total equity-$180.5M+2.9%
Total assets$2.9B+8.0%

Cash flow

See full
Operating cash flow-$59.0M-107%
CapEx$1.2M-30.6%
Free cash flow-$60.2M-107%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$5.64B+40.3%
Enterprise value$5.2B+77.3%
P/S6.8×+4.6×

Profitability

See full
Operating margin1.6%-38.7pp

Returns & leverage

See full
Current ratio2.4×-1.5×

Segments

By product

See full
Sephience$124.6M—
Translarna$59.0M—
Emflaza$21.5M—
Other Products$11.0M—
Upstaza And Kebilidi$9.6M—

By segment

See full
Life Science$272.6M-76.8%

FAQ

When did PTC Therapeutics report Q1 2026 earnings?
PTC Therapeutics (PTCT) reported Q1 2026 earnings on May 7, 2026 after market close.
What were PTC Therapeutics's Q1 2026 revenue and EPS?
PTC Therapeutics reported revenue of $272.6M and eps of $-0.03 for Q1 2026.
Did PTC Therapeutics beat estimates in Q1 2026?
Revenue beat the consensus estimate of $217.4M by $55.1M. EPS beat the consensus estimate of $-0.45 by $0.42.
How did PTC Therapeutics's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 76.8% from $1.2B a year earlier.
Where can I find PTC Therapeutics's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001070081-26-000011) and the 10-Q periodic report (0001070081-26-000012) directly on SEC EDGAR. The filing index links above go to sec.gov.